
Blueprint Medicines Corporation BPMC
Quartalsbericht 2025-Q1
hinzugefügt 01.05.2025
Blueprint Medicines Corporation P/E 2011-2026 | BPMC
P/E Jährlich Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -88.8 | -10.5 | -4.76 | -9.73 | 19.5 | -8.84 | -13.1 | -20.7 | -12.6 | -5.43 | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 19.5 | -88.8 | -15.5 |
P/E anderer Aktien in der Pharmaeinzelhändler
| Name | P/E | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-66.5 | $ 3.62 | -1.09 % | $ 8.71 B | ||
|
BioNTech SE
BNTX
|
6.11 | $ 98.41 | 1.77 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
12.2 | $ 4.71 | 4.9 % | $ 760 M | ||
|
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
-2.73 | $ 8.74 | 0.23 % | $ 86.4 M | ||
|
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | ||
|
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
-4.52 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
12.7 | $ 21.38 | 0.09 % | $ 999 M | ||
|
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - | ||
|
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-62.5 | $ 1.56 | 6.12 % | $ 401 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | $ 3.05 | 4.45 % | $ 5.02 M | ||
|
Aquestive Therapeutics
AQST
|
-5.58 | $ 4.15 | -0.95 % | $ 444 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-213 | $ 25.09 | 4.02 % | $ 3.19 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-0.544 | - | -2.5 % | $ 5.88 M | ||
|
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
3.63 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-1.12 | $ 1.48 | 0.68 % | $ 394 M | ||
|
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B | ||
|
Evogene Ltd.
EVGN
|
-2.18 | $ 0.82 | 0.02 % | $ 27.9 M | ||
|
AVROBIO
AVRO
|
4.63 | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | ||
|
bluebird bio
BLUE
|
-0.316 | - | - | $ 546 M | ||
|
AstraZeneca PLC
AZN
|
706 | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | ||
|
Cabaletta Bio
CABA
|
-1.69 | $ 3.26 | 1.87 % | $ 328 M | ||
|
Cidara Therapeutics
CDTX
|
-0.873 | - | - | $ 1.41 B | ||
|
Akari Therapeutics, Plc
AKTX
|
-467 | $ 4.63 | 9.01 % | $ 312 B | ||
|
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | ||
|
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | ||
|
Baudax Bio
BXRX
|
-0.0133 | - | 0.59 % | $ 63 K | ||
|
Alpine Immune Sciences
ALPN
|
-4.65 | - | - | $ 2.17 B |